Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
NeoGenomics, Inc. (NEO) had Stock-Based Compensation of $33.27M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$187.80M |
|
$-27.13M |
|
$107.35M |
|
$80.45M |
|
$214.81M |
|
$-27.01M |
|
$0.62M |
|
$-26.39M |
|
$-26.39M |
|
$-27.13M |
|
$-27.13M |
|
$-27.13M |
|
$-27.13M |
|
$-27.01M |
|
$-10.20M |
|
128.41M |
|
128.41M |
|
$-0.21 |
|
$-0.21 |
|
| Balance Sheet Financials | |
$382.46M |
|
$85.47M |
|
$992.32M |
|
$1.37B |
|
$97.87M |
|
$341.48M |
|
$438.62M |
|
$536.49M |
|
$838.29M |
|
$19.78M |
|
$838.29M |
|
128.88M |
|
| Cash Flow Statement Financials | |
$3.89M |
|
$-6.03M |
|
$-200.72M |
|
$367.01M |
|
$164.12M |
|
$-202.90M |
|
|
Stock-Based Compensation |
$33.27M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.91 |
|
-- |
|
-- |
|
0.29 |
|
0.41 |
|
42.84% |
|
-14.38% |
|
-14.38% |
|
-- |
|
-14.05% |
|
-14.45% |
|
$-15.25M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
3.77 |
|
1.21 |
|
74.42 |
|
-3.24% |
|
-137.13% |
|
-1.97% |
|
-2.30% |
|
$6.50 |
|
$-0.12 |
|
$0.03 |
|